



## PEP-Therapy welcomes Ursula Vogel to its Board of Directors

**Paris (France), August 23, 2022 – PEP-Therapy, a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology, is pleased to announce the joining of Ursula Vogel, PhD as an independent Board of Directors member.**

The appointment of Dr. Ursula Vogel comes at a time when the company is conducting a Phase Ia/b clinical trial on its lead product, PEP-010, and preparing new strategic partnerships to bring the company to its next inflection stage. She joins the company's Board of Directors that is composed of representatives of its international investors and a seasoned biotech entrepreneur.

Dr. Ursula Vogel has over 25 years of global biopharma industry experience, having started her career in R&D at Merck Sharp & Dohme and Sanofi, followed by a pivotal leadership role at pioneering US biotech Genetics Institute where she set up and managed the European affiliate until its acquisition by Wyeth (now Pfizer) and where she was a major contributor to the success of two marketed products (Infuse®/InductOs, BeneFIX®). She has since built an independent advisory practice, helping conclude a multitude of licensing transactions and bring biopharmas to successful exits. Her focus areas are Business & Corporate Development, and C-level or Board level representation. She holds a PhD from Cambridge University, and an MBA from INSEAD.

*"We are excited to welcome Ursula to our Board" said **Antoine Prestat, CEO and co-founder of PEP-Therapy.** "Her global dealmaking experience will provide a valuable contribution to PEP-Therapy as we ramp up our corporate development activities. Her thorough knowledge of the global biotech and pharma ecosystems will contribute to identifying the best opportunities for the development of PEP-010 and the company."*

PEP-010 is a first-in-class therapeutic peptide, a pro-apoptotic agent, currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors, poor prognosis and few therapeutic alternatives. The trial is conducted in partnership with leading European cancer centers, Institut Curie, Gustave Roussy, and François Baclesse.

xxx

### **About PEP-Therapy**

PEP-Therapy is a Paris-based clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology. PEP-010, leading drug candidate, is a pro-apoptotic agent currently evaluated in a Phase Ia/b clinical trial. The company also develops a pipeline of peptide-based products in oncology.

PEP-Therapy, which was founded in 2014 and builds on research from Sorbonne University and Institut Curie, is backed by international investors: Seventure Partners (Quadrivium 1 Seed Fund), Anaxago, i&i Prague, Italian Angels for Growth (IAG), Doorway, Magna Capital Partners (MCP), Business Angels des Grandes Ecoles (BADGE), and Jérôme Majoie (former Managing Director of Laboratoires Fournier affiliates (USA, UK, Sweden, Japan), CEO of La Fondation Fournier-Majoie).

For more information, please visit [www.pep-therapy.com](http://www.pep-therapy.com).

### **Contact**

**PEP-Therapy:** Antoine Prestat, CEO & co-founder

[hello.pep@pep-therapy.com](mailto:hello.pep@pep-therapy.com)

+33 1 81 70 76 82